Literature DB >> 24172156

Toxin-producing Clostridium difficile strains as long-term gut colonizers in healthy infants.

Ingegerd Adlerberth1, Haihui Huang, Erika Lindberg, Nils Åberg, Bill Hesselmar, Robert Saalman, Carl Erik Nord, Agnes E Wold, Andrej Weintraub.   

Abstract

Clostridium difficile is a colonizer of the human gut, and toxin-producing strains may cause diarrhea if the infectious burden is heavy. Infants are more frequently colonized than adults, but they rarely develop C. difficile disease. It is not known whether strains of C. difficile differ in the capacity to colonize and persist in the human gut microbiota. Here, we strain typed isolates of C. difficile that had colonized 42 healthy infants followed from birth to ≥12 months of age by using PCR ribotyping of the 16S-23S rRNA intergenic spacer region. The isolates were also characterized regarding carriage of the toxin genes tcdA, tcdB, and cdtA/B and the capacity to produce toxin B in vitro. Most strains (71%) were toxin producers, and 51% belonged to the 001 or 014 ribotypes, which often cause disease in adults. These ribotypes were significantly more likely than others to persist for ≥6 months in the infant micobiota, and they were isolated from 13/15 children carrying such long-term-colonizing strains. Ribotype 001 strains were often acquired in the first week of life and attained higher population counts than other C. difficile ribotypes in newborn infants' feces. Several toxin-negative ribotypes were identified, two of which (GI and GIII) were long-term colonizers, each found in one infant. Our results suggest that the toxin-producing C. difficile ribotypes 001 and 014 have special fitness in the infantile gut microbiota. Toxin-producing strains colonizing young children for long time periods may represent a reservoir for strains causing disease in adults.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24172156      PMCID: PMC3911410          DOI: 10.1128/JCM.01701-13

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  37 in total

1.  Clostridium difficile infection in Europe: a hospital-based survey.

Authors:  Martijn P Bauer; Daan W Notermans; Birgit H B van Benthem; Jon S Brazier; Mark H Wilcox; Maja Rupnik; Dominique L Monnet; Jaap T van Dissel; Ed J Kuijper
Journal:  Lancet       Date:  2011-01-01       Impact factor: 79.321

Review 2.  Asymptomatic colonization by Clostridium difficile in infants: implications for disease in later life.

Authors:  Sushrut Jangi; J Thomas Lamont
Journal:  J Pediatr Gastroenterol Nutr       Date:  2010-07       Impact factor: 2.839

Review 3.  Establishment of the gut microbiota in Western infants.

Authors:  I Adlerberth; A E Wold
Journal:  Acta Paediatr       Date:  2009-02       Impact factor: 2.299

4.  Recurrent infection with epidemic Clostridium difficile in a peripartum woman whose infant was asymptomatically colonized with the same strain.

Authors:  Michelle T Hecker; Michelle M Riggs; Claudia K Hoyen; Christina Lancioni; Curtis J Donskey
Journal:  Clin Infect Dis       Date:  2008-03-15       Impact factor: 9.079

5.  A case-control study of community-associated Clostridium difficile infection.

Authors:  M H Wilcox; L Mooney; R Bendall; C D Settle; W N Fawley
Journal:  J Antimicrob Chemother       Date:  2008-04-22       Impact factor: 5.790

6.  Increase in Clostridium difficile-related hospitalizations among infants in the United States, 2000-2005.

Authors:  Marya D Zilberberg; Andrew F Shorr; Marin H Kollef
Journal:  Pediatr Infect Dis J       Date:  2008-12       Impact factor: 2.129

7.  Comparison of a commercial multiplex real-time PCR to the cell cytotoxicity neutralization assay for diagnosis of clostridium difficile infections.

Authors:  Haihui Huang; Andrej Weintraub; Hong Fang; Carl Erik Nord
Journal:  J Clin Microbiol       Date:  2009-09-09       Impact factor: 5.948

Review 8.  Clostridium difficile infection: new developments in epidemiology and pathogenesis.

Authors:  Maja Rupnik; Mark H Wilcox; Dale N Gerding
Journal:  Nat Rev Microbiol       Date:  2009-07       Impact factor: 60.633

9.  High circulating immunoglobulin A levels in infants are associated with intestinal toxigenic Staphylococcus aureus and a lower frequency of eczema.

Authors:  A-C Lundell; B Hesselmar; I Nordström; R Saalman; H Karlsson; E Lindberg; N Aberg; I Adlerberth; A E Wold; A Rudin
Journal:  Clin Exp Allergy       Date:  2009-03-16       Impact factor: 5.018

10.  Gut microbiota and development of atopic eczema in 3 European birth cohorts.

Authors:  Ingegerd Adlerberth; David P Strachan; Paolo M Matricardi; Siv Ahrné; Lia Orfei; Nils Aberg; Michael R Perkin; Salvatore Tripodi; Bill Hesselmar; Robert Saalman; Anthony R Coates; Carmen L Bonanno; Valentina Panetta; Agnes E Wold
Journal:  J Allergy Clin Immunol       Date:  2007-06-29       Impact factor: 10.793

View more
  21 in total

Review 1.  Neonatal mucosal immunology.

Authors:  N Torow; B J Marsland; M W Hornef; E S Gollwitzer
Journal:  Mucosal Immunol       Date:  2016-09-21       Impact factor: 7.313

2.  Reducing C. difficile in children: An agent-based modeling approach to evaluate intervention effectiveness.

Authors:  Anna K Barker; Elizabeth Scaria; Oguzhan Alagoz; Ajay K Sethi; Nasia Safdar
Journal:  Infect Control Hosp Epidemiol       Date:  2020-02-13       Impact factor: 3.254

Review 3.  Battling Enteropathogenic Clostridia: Phage Therapy for Clostridioides difficile and Clostridium perfringens.

Authors:  Jennifer Venhorst; Jos M B M van der Vossen; Valeria Agamennone
Journal:  Front Microbiol       Date:  2022-06-13       Impact factor: 6.064

Review 4.  Understanding Clostridium difficile Colonization.

Authors:  Monique J T Crobach; Jonathan J Vernon; Vivian G Loo; Ling Yuan Kong; Séverine Péchiné; Mark H Wilcox; Ed J Kuijper
Journal:  Clin Microbiol Rev       Date:  2018-03-14       Impact factor: 26.132

5.  Longitudinal Investigation of Carriage Rates, Counts, and Genotypes of Toxigenic Clostridium difficile in Early Infancy.

Authors:  Hiroyuki Kubota; Hiroshi Makino; Agata Gawad; Akira Kushiro; Eiji Ishikawa; Takafumi Sakai; Takuya Akiyama; Kazunori Matsuda; Rocio Martin; Jan Knol; Kenji Oishi
Journal:  Appl Environ Microbiol       Date:  2016-09-16       Impact factor: 4.792

6.  Clostridium difficile recurrence is characterized by pro-inflammatory peripheral blood mononuclear cell (PBMC) phenotype.

Authors:  Mary B Yacyshyn; Tara N Reddy; Lauren R Plageman; Jiang Wu; Amy R Hollar; Bruce R Yacyshyn
Journal:  J Med Microbiol       Date:  2014-07-07       Impact factor: 2.472

7.  Potential causative agents of acute gastroenteritis in households with preschool children: prevalence, risk factors, clinical relevance and household transmission.

Authors:  M Heusinkveld; L Mughini-Gras; R Pijnacker; H Vennema; R Scholts; K W van Huisstede-Vlaanderen; T Kortbeek; M Kooistra-Smid; W van Pelt
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-07-02       Impact factor: 3.267

Review 8.  Controversies Surrounding Clostridium difficile Infection in Infants and Young Children.

Authors:  Maribeth R Nicholson; Isaac P Thomsen; Kathryn M Edwards
Journal:  Children (Basel)       Date:  2014-06-13

9.  Clostridium difficile colonization and antibiotics response in PolyFermS continuous model mimicking elderly intestinal fermentation.

Authors:  Sophie Fehlbaum; Christophe Chassard; Sophie Annick Poeker; Muriel Derrien; Candice Fourmestraux; Christophe Lacroix
Journal:  Gut Pathog       Date:  2016-12-01       Impact factor: 4.181

10.  Alberta Provincial Pediatric EnTeric Infection TEam (APPETITE): epidemiology, emerging organisms, and economics.

Authors:  Stephen B Freedman; Bonita E Lee; Marie Louie; Xiao-Li Pang; Samina Ali; Andy Chuck; Linda Chui; Gillian R Currie; James Dickinson; Steven J Drews; Mohamed Eltorki; Tim Graham; Xi Jiang; David W Johnson; James Kellner; Martin Lavoie; Judy MacDonald; Shannon MacDonald; Lawrence W Svenson; James Talbot; Phillip Tarr; Raymond Tellier; Otto G Vanderkooi
Journal:  BMC Pediatr       Date:  2015-07-31       Impact factor: 2.125

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.